Find a guideline using key words – the classic approach

In Week 2, we learned about the fictitious Canadian company QueGen and their strategy for developing a new version of Glybera, a gene therapy product that was originally developed for the treatment of lipoprotein lipase deficiency (LPLD) and approved by the EMA, but was later withdrawn from the market.